A Phase 4 interventional study of Decapeptyl® SR 22.5mg and Decapeptyl® SR 11.25mg; Prostap® 3 DCS 11.25mg; Zoladex® LA 10.8mg in Prostate Cancer, sponsored by Ipsen. Terminated at 35 sites in United Kingdom. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-23.
Sponsored by Ipsen · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing triptorelin in Prostatic Neoplasms — 6 open to participants now, 6 under way, 3 of them phase 3. triptorelin · Prostatic Neoplasms.
Among the 28 studies testing triptorelin in Prostatic Neoplasms, this one is the 25th largest by enrollment, is one of 3 that started in 2012, is one of 6 in phase 4, and was the 13th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →6 of the 28 studies testing triptorelin in Prostatic Neoplasms are open now, in 5 countries. Recruiting first, the newest first:
Baptist Health South Florida · Sites in United States
Ages 18+ · Men only
Cancer Research Antwerp · Sites in Belgium
Ages 18+ · Men only
Ottawa Hospital Research Institute · Sites in Canada
Ages 18+ · Men only
Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic · Sites in Spain
Ages 18+
Marco Lorenzo Bonu · Sites in Italy
Ages 18–80 · Men only
By country, each count listing its studies:
triptorelin: first FDA approval 2000 (TRELSTAR). What it is approved for, and how studies give it, is on its page →
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 8 · Phase 3 13 · Phase 4 6
First in 2002; this study’s year is marked. 3 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 27 is below the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 120 across the 28 interventional studies. Of the 17 that completed or were terminated, 10 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 28 have an industry lead sponsor. The 10 most frequent:
Ipsen is the lead sponsor of 289 studies on the registry; 17 are open to participants now.
Of its 26 completed or terminated interventional studies of FDA-regulated products, 22 (85%) have results posted.
26 studies in Prostatic Neoplasms by Ipsen: none open now, none under way, none of them phase 3. Of 26 finished, 12 (46%) have results posted.
Among the 26 studies in Prostatic Neoplasms by Ipsen, this one is the 12th largest by enrollment of the 16 interventional ones that give a count, is one of 4 that started in 2012, is one of 2 in phase 4, and was the 11th registered.
Ipsen’s Prostatic Neoplasms studies by the year they started, since 2006.
1 of the studies testing triptorelin in Prostatic Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05851547Ottawa Hospital Research InstituteDose Escalation For INtraprostatic LEsions | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 28 studies testing triptorelin in Prostatic Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Ipsen’s 26 in Prostatic Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to demonstrate that treatment with a 6-monthly injection of hormone therapy is as good and as well tolerated as the standard 3-monthly hormone therapy injections available for treating prostate cancer. The study will also aim to answer whether both doctors and patients would prefer treatment with a 6-monthly injection rather than injections every 3 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
In addition:
For patients with metastatic prostate cancer (M+) and a Gleason score
≤ 7, LHRH agonist injection (any formulation) must have been initiated within the last 2 years from Baseline,
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Decapeptyl® SR 22.5mg
One of the following: Decapeptyl® SR 11.25mg (Triptorelin), Prostap® 3 DCS 11.25mg, Zoladex® LA 10.8mg
Drug: Decapeptyl® SR 11.25mg; Prostap® 3 DCS 11.25mg; Zoladex® LA 10.8mg
22.5mg, intramuscular injection, given on day 1 / month 0 \& month 6 (+/- 7 days).
Also known as: Triptorelin
For Decapeptyl® SR 11.25mg: 11.25 mg, intramuscular injection For Prostap® 3 DCS 11.25mg: 11.25mg, depot injected subcutaneously For Zoladex® LA 10.8mg: 10.8mg, depot injected subcutaneously into anterior abdominal wall
Also known as: Triptorelin
Percentage of Participants Maintaining Biochemical Castration
Patients with serum total testosterone (STT) level lower than 0.5 ng/mL after 6 months of treatment.
Time frame: 6 months
Percentage of Participants Maintaining Biochemical Castration After 12 Months of Treatment.
Patients with serum total testosterone (STT) level lower than 0.5 ng/mL, 12 months after randomisation..
Time frame: 12 months
Percentage of Participants Demonstrating Stable Prostate-specific Antigen (PSA) Levels
Stable PSA level was noted as value either lower or less than 25% higher than the baseline value, or PSA value ≤0.5 ng/mL higher than the baseline value, if value ≥25% higher than the baseline value.
Time frame: 6 and 12 months
Change From Baseline in Quality of Life Using EuroQol 5 Dimensions 5 Levels [EQ-5D-5L] Questionnaire.
The EQ-5D-5L questionnaire consisted of a description of raw data which comprised of five dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). Each dimension had five levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The visual analogical scale of the EQ-5D-5L questionnaire was numbered from 0 to 100 (0 meaning the worst health the patient can imagine and 100 the best health the patient can imagine).
Time frame: Baseline and Month 12
Change From Baseline in Patient Satisfaction With Medication Using Treatment Satisfaction Questionnaire for Medication (TSQM Version II)
TSQM comprised of four dimensions: effectiveness, side effects, convenience and overall global satisfaction. Each score ranged from 0 to 100. For effectiveness, convenience and overall global satisfaction scores, 0 indicated an extreme dissatisfaction and 100 indicated an extreme satisfaction. For side effects score, 0 indicated an extreme dissatisfaction and 100 indicated no dissatisfaction at all.
Time frame: 6 and 12 month
Patient Satisfaction With Treatment.
Using a non-validated study-specific descriptive Likert-type scale (with no units) comprising a simple six-question patient questionnaire.
Time frame: Month 12
Percentage of Participants Who Changed Injection Frequency After Completion of the Study
Time frame: Month 12
35 subjects screened and 27 subjects were enrolled. Following enrollment, 21 patients were randomised before the study was prematurely discontinued.
| Milestone | Decapeptyl® SR 22.5mg | Current 3-monthly LHRH Agonist |
|---|---|---|
| Started | 14 | 7 |
| Completed | 4 | 1 |
| Not completed | 10 | 6 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Study termination | 9 | 6 |
Patients with serum total testosterone (STT) level lower than 0.5 ng/mL after 6 months of treatment.
| percentage of participants | Decapeptyl® SR 22.5mg | Current 3-monthly LHRH Agonist |
|---|---|---|
| Percentage of Participants Maintaining Biochemical Castration | 92.9 | 100 |
Patients with serum total testosterone (STT) level lower than 0.5 ng/mL, 12 months after randomisation..
| percentage of participants | Decapeptyl® SR 22.5mg | Current 3-monthly LHRH Agonist |
|---|---|---|
| Percentage of Participants Maintaining Biochemical Castration After 12 Months of Treatment. | 22.2 | 25.0 |
Stable PSA level was noted as value either lower or less than 25% higher than the baseline value, or PSA value ≤0.5 ng/mL higher than the baseline value, if value ≥25% higher than the baseline value.
| percentage of participants | Decapeptyl® SR 22.5mg | Current 3-monthly LHRH Agonist |
|---|---|---|
| 6 months (n = 13, 7) | 84.6 | 100 |
| 12 months (n = 2, 1) | 50 | 100 |
The EQ-5D-5L questionnaire consisted of a description of raw data which comprised of five dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). Each dimension had five levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The visual analogical scale of the EQ-5D-5L questionnaire was numbered from 0 to 100 (0 meaning the worst health the patient can imagine and 100 the best health the patient can imagine).
| units on a scale | Decapeptyl® SR 22.5mg | Current 3-monthly LHRH Agonist |
|---|---|---|
| Change From Baseline in Quality of Life Using EuroQol 5 Dimensions 5 Levels [EQ-5D-5L] Questionnaire. | 71.7 (40.4 to 102.9) | 70.0 (-57.1 to 197.1) |
TSQM comprised of four dimensions: effectiveness, side effects, convenience and overall global satisfaction. Each score ranged from 0 to 100. For effectiveness, convenience and overall global satisfaction scores, 0 indicated an extreme dissatisfaction and 100 indicated an extreme satisfaction. For side effects score, 0 indicated an extreme dissatisfaction and 100 indicated no dissatisfaction at all.
| units on a scale | Decapeptyl® SR 22.5mg | Current 3-monthly LHRH Agonist |
|---|---|---|
| Baseline to 6 months - Effectiveness (n= 13, 7) | 3.2 (-12.5 to 18.9) | 13.1 (-10.8 to 37.0) |
| Baseline to 12 months - Effectiveness (n= 3, 2) | -33.3 (-74.7 to 8.1) | -12.5 (-383.1 to 358.1) |
| Baseline to 6 months - Side Effects (n= 13, 7) | -2.6 (-12.9 to 7.8) | 4.8 (-6.0 to 15.5) |
| Baseline to 12 months - Side Effects (n= 3, 2) | -25.0 (-115.2 to 65.2) | 12.5 (-146.3 to 171.3) |
| Baseline to 6 months - Convenience (n= 13, 7) | 4.7 (-6.3 to 15.7) | 2.0 (-9.8 to 13.7) |
| Baseline to 12 months - Convenience (n= 3, 2) | -1.9 (-36.6 to 32.9) | 2.8 (-103.1 to 108.7) |
| Baseline to 6months -Global Satisfaction(n= 12, 6) | -0.7 (-15.9 to 14.5) | -4.2 (-11.5 to 3.2) |
| Baseline to 12months -Global Satisfaction(n= 2, 2) | -12.5 (-171.3 to 146.3) | 4.2 (-48.8 to 57.1) |
Using a non-validated study-specific descriptive Likert-type scale (with no units) comprising a simple six-question patient questionnaire.
No measurements were reported for this outcome.
| percentage of participants | Decapeptyl® SR 22.5mg | Current 3-monthly LHRH Agonist |
|---|---|---|
| Percentage of Participants Who Changed Injection Frequency After Completion of the Study | 80 | 0 |
Collected over Up to 12 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Decapeptyl® SR 22.5mg | — | 2/14 (14.3%) | 12/14 (85.7%) |
| Current 3-monthly LHRH Agonist | — | 0/7 (0%) | 7/7 (100%) |
| Event | Decapeptyl® SR 22.5mg | Current 3-monthly LHRH Agonist |
|---|---|---|
| PneumoniaInfections and infestations | 1/14 | 0/7 |
| Subdural haematomaInjury, poisoning and procedural complications | 1/14 | 0/7 |
| Disease progressionGeneral disorders | 1/14 | 0/7 |
| Event | Decapeptyl® SR 22.5mg | Current 3-monthly LHRH Agonist |
|---|---|---|
| DizzinessNervous system disorders | 5/14 | 0/7 |
| Lower respiratory tract infectionInfections and infestations | 3/14 | 1/7 |
| Back painMusculoskeletal and connective tissue disorders | 3/14 | 1/7 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 3/14 | 0/7 |
| Oedema peripheralGeneral disorders | 2/14 | 0/7 |
| BronchitisInfections and infestations | 1/14 | 1/7 |
| Urinary tract infectionInfections and infestations | 2/14 | 0/7 |
| HeadacheNervous system disorders | 2/14 | 0/7 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 2/14 | 0/7 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/14 | 0/7 |
| Age, Continuous(years) | Decapeptyl® SR 22.5mg | Current 3-monthly LHRH Agonist | Total |
|---|---|---|---|
| Mean | 77.2 ± 5.4 | 78.7 ± 9.3 | 77.7 ± 6.7 |
| Sex: Female, Male(Participants) | Decapeptyl® SR 22.5mg | Current 3-monthly LHRH Agonist | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 14 | 7 | 21 |
| Employment status/Occupation(participants) | Decapeptyl® SR 22.5mg | Current 3-monthly LHRH Agonist | Total |
|---|---|---|---|
| Employed | 2 | 1 | 3 |
| Retired | 12 | 6 | 18 |
The record gives a start of Aug 2012, a primary completion of Feb 2014 and a completion of Feb 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2015, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Triptorelin